South Australian biotech ships up to Boston
A record-high number of South Australian companies will be exposed to thousands of global investors during a trade mission in Boston this June, as the North Terrace Biotech precinct gains worldwide attention.
Supported by the South Australian Government, the 16 local delegates – the largest group ever to attend – will converge on the BIO 23 International Convention, the world’s biggest biotech event set to attract more than 15,000 participants.
As South Australia’s relationship with the United States strengthens following the AUKUS agreement, the 2023 event is the perfect time to capitalise on investment opportunities in the State’s advanced manufacturing sector.
Trade and Investment Minister Nick Champion will help lead the business mission, with the conference providing a platform to showcase the State’s world-class health and medical capabilities located on North Terrace – and pitch directly to international biotech companies.
South Australian representatives include specialists in clinical trials and drug development, along with medical device manufacturers and academia.
The University of South Australia is among those attending, enabling the university to explore opportunities within their medical research and development sector, in addition to pharmaceutical, biotech and life sciences industries.
Biotech and pharma leaders at the event will see first-hand UniSA’s renowned work in cancer research, biomaterials engineering, pharmaceutical innovation, artificial intelligence and research commercialisation – paving the way for future partnerships.
Other local representation includes: Adelaide Intermediary Program/MTP Connect; Agilex Biolabs; Australian Teletrials Program; Avance Clinical; Bellberry; Bentleys R&D Incentives; BioCina; BiomeBank; Carina Biotech; CMAX Clinical research; Commercial and General; Mayne Pharma Services; Southern Oncology Clinical Research Unit; Syneos Health; and Yuhan ANZ.
More than $6 million worth of deals were struck for South Australian stakeholders at last year’s BIO event.
Minister Champion will also meet with key investors, businesses, organisations, institutes and government representatives across a range of sectors – with a push to build South Australia’s leading role in the historic AUKUS agreement and boost the local defence industry.
Attracting global investment into South Australia’s food and wine, advanced manufacturing and skills, data economy and green energy sectors will also be a focus of the trip.
Innovative housing models, urban development and planning for vibrant and sustainable cities will also feature on the Minister’s itinerary.
The United States is the State’s second largest export market with a value estimated at $1.58 billion in the year ending March 2023. The US is also SA’s single largest foreign investor.
Supported by the South Australian Government, the 16 local delegates – the largest group ever to attend – will converge on the BIO 23 International Convention, the world’s biggest biotech event set to attract more than 15,000 participants.
As South Australia’s relationship with the United States strengthens following the AUKUS agreement, the 2023 event is the perfect time to capitalise on investment opportunities in the State’s advanced manufacturing sector.
Trade and Investment Minister Nick Champion will help lead the business mission, with the conference providing a platform to showcase the State’s world-class health and medical capabilities located on North Terrace – and pitch directly to international biotech companies.
South Australian representatives include specialists in clinical trials and drug development, along with medical device manufacturers and academia.
The University of South Australia is among those attending, enabling the university to explore opportunities within their medical research and development sector, in addition to pharmaceutical, biotech and life sciences industries.
Biotech and pharma leaders at the event will see first-hand UniSA’s renowned work in cancer research, biomaterials engineering, pharmaceutical innovation, artificial intelligence and research commercialisation – paving the way for future partnerships.
Other local representation includes: Adelaide Intermediary Program/MTP Connect; Agilex Biolabs; Australian Teletrials Program; Avance Clinical; Bellberry; Bentleys R&D Incentives; BioCina; BiomeBank; Carina Biotech; CMAX Clinical research; Commercial and General; Mayne Pharma Services; Southern Oncology Clinical Research Unit; Syneos Health; and Yuhan ANZ.
More than $6 million worth of deals were struck for South Australian stakeholders at last year’s BIO event.
Minister Champion will also meet with key investors, businesses, organisations, institutes and government representatives across a range of sectors – with a push to build South Australia’s leading role in the historic AUKUS agreement and boost the local defence industry.
Attracting global investment into South Australia’s food and wine, advanced manufacturing and skills, data economy and green energy sectors will also be a focus of the trip.
Innovative housing models, urban development and planning for vibrant and sustainable cities will also feature on the Minister’s itinerary.
The United States is the State’s second largest export market with a value estimated at $1.58 billion in the year ending March 2023. The US is also SA’s single largest foreign investor.